Clinical Trial Update: Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and efficacy of MY008211A in patients with Paroxysmal nocturnal hemoglobinuria who have residual anemia despite ant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• MY008211A

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: RECRUITING